Vanessa Tyrrell

Co-Head of Division - Peronalised Medicine

Children's Cancer Institute Australia

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Vanessa Tyrrell is the Co-Head of Division for Personalised Medicine at the Children's Cancer Institute Australia. Her research primarily focuses on the implementation and implications of precision medicine in treating high-risk pediatric cancers. Recent publications include significant contributions to understanding economic costs, therapeutic strategies, and the perspectives of parents and patients in precision medicine trials. Dr. Tyrrell's work aims to identify new therapeutic opportunities and improve outcomes for children diagnosed with cancer.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

Head

Children's Cancer Institute Australia

AUSTRALIA

View details

Chris Jacobs

Associate Professor in Genetic and Genomic Counselling

University of Surrey

UNITED KINGDOM

View details

Rebecca Daly

University of New South Wales - Randwick Campus

AUSTRALIA

View details

Chelsea Mayoh

Children's Cancer Institute Australia

AUSTRALIA

View details

Joseph Rosenbluh

Lab Head

MONASH UNIVERSITY

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vanessa Tyrrell

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The economic costs of precision medicine for clinical translational research among children with high-risk cancer

Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities

Parents’ expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial

Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives

Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: The PREDICT study

In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer

Collaborators (14)

Jacqueline Hunter

Gabor Tax

Rebecca Deyell

Brett Stringer

Yuyan Chen

Rupendra Shrestha

Karen MacKenzie

Mark Cowley

Alvin Kamili

Richard Lock

Chris Jacobs

Rebecca Daly

Chelsea Mayoh

Joseph Rosenbluh

Make your next move.